Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04451902
Other study ID # COVID19-RareSkin
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 30, 2020
Est. completion date December 31, 2022

Study information

Verified date September 2021
Source Imagine Institute
Contact Rébecca GENE
Phone 0144492582
Email rebecca.gene@aphp.fr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This is a European observational cohort study (data research) involving multiple centres to look at the potential impact of COVID infection on patients with rare skin diseases examining factors such as comorbidity, protection factors, and clinical and/or therapeutic factors. The data collected may provide additional information on the situation of patients and, on a wider basis, provide useful data applicable to the general population.


Description:

Medical and demographic data will be collected from the medical records of patients. The data required will be specified in Appendix 1 (collection form). Patients will be identified by their initials (first letter of their surname and first name); The study will last for one year to cover the COVID-19 epidemic in France (which includes the areas of mainland France and its overseas departments and territories) and in Europe, via the ERN-Skin European Network. The frequency of severe forms of COVID-19 will be calculated with a bilateral 95% confidence interval using, as a numerator, the number of patients with a severe form of COVID-19 and, as a denominator, the number of patients with a COVID-19 diagnosis confirmed by PCR, chest scan, serological assay or by suggestive clinical signs during the medical consultation. A severe form of COVID is defined as a case requiring hospitalisation in an intensive care unit, requiring resuscitation, or resulting in death. Analysis of the impact of COVID-19 infection on rare skin diseases: complications, potential comorbidity factors, impact on the management of chronic conditions (change in treatment) and the experience of patients. The results of the analysis may be compared with those obtained for other groups of diseases. Gaining a better understanding of high-risk situations, as well as any aggravation or protective factors, should enable us to issue recommendations adapted to this kind of disease but that may also be useful for the general population. This type of study may also provide "reassurance" to patients with rare diseases who have many questions during this period of epidemic and heightened concern.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 31, 2022
Est. primary completion date April 30, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patient with a rare skin disease, - Patient of any age (paediatric or adult), - Patient with suspected COVID-19 infection (remote consultation, face-to-face consultation, general practitioner, hospital physician), - Patient in contact with a subject infected with the COVID-19 virus, - Asymptomatic patient for COVID-19 viral infection but with a positive serology, - Study information given to the patient and/or to their legal representative, - Patient who has been informed and has agreed to this data collection process. Exclusion Criteria: - Patients not suffering from a rare skin disease, - Patient and/or their legal representative who object to their participation in the study at the presentation of the information leaflet, - Adult patient unable to understand the implications and constraints of the study, - Protected adult subject to guardianship or safeguarding measures.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Czechia University Hospital Brno - EB Centrum CR Dermatolog Brno
France Hôpital de l'Archet 2 (CHU de Nice) Nice Alpes-Maritimes
France Hôpital Necker - Enfants malades (AP-HP) Paris Ile-de-France
France Hôpital Saint Louis (AP-HP) Paris Ile-de-France
France Hôpital Charles Nicolle (CHU de Rouen) Rouen Seine-Maritime
France Hôpital de Clocheville (CHRU de Tours) Tours Indre-et-Loire
France Hôpital de Brabois (CHU de Nancy) Vandœuvre-lès-Nancy Meurthe-et-Moselle
Germany Städtisches Klinikum Dessau, Dessau Medical Center Dessau Sachsen-Anhalt
Germany University Hospital of Erlangen - ZSEER - Zentrum für Seltene Erkrankungen Erlangen Erlangen Bavaria
Italy Azienda USL Toscana Centro Firenze Toscana
Italy IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano Lombardia
Italy Istituto Dermopatico dell'Immacolata Roma Lazio
Lithuania Hospital of Lithuanian University of Health Sciences Kauno Klinikos Kaunas

Sponsors (1)

Lead Sponsor Collaborator
Imagine Institute

Countries where clinical trial is conducted

Czechia,  France,  Germany,  Italy,  Lithuania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Analysis of the impact of COVID-19 infection on rare skin diseases: complications Frequency of hospitalisations related to suspected and confirmed cases of Covid-19 infection and consequences Baseline
Primary Analysis of the impact of COVID-19 infection on rare skin diseases: potential comorbidity factors Frequency of hospitalisations related to suspected and confirmed cases of Covid-19 infection and analysis of associated factors: age, gender, pathology, comorbidities, medications Baseline
Primary Analysis of the impact of COVID-19 infection on rare skin diseases: impact on the management of chronic conditions (change in treatment) Frequency of confirmed and suspected unconfirmed Covid-19 infections; description of clinical signs and signs of an impact on the chronic disease; description of possible therapeutic changes due to the Covid-19 infections Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05794217 - A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
Completed NCT03680365 - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Completed NCT03290469 - NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants N/A
Not yet recruiting NCT05955794 - Vocal Pattern Assessment as a New Key to Identifying Rare Syndromes N/A
Recruiting NCT04429750 - Intact Cord Resuscitation in CDH N/A
Not yet recruiting NCT04152876 - Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power
Recruiting NCT03683966 - MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
Not yet recruiting NCT04319796 - European Registry on Rare Neurological Diseases
Completed NCT02736565 - Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma Phase 1
Completed NCT05070988 - Oral Health Related Quality of Life of Patients With Rare Diseases: a Qualitative Approach
Completed NCT03563677 - Dual Guidance Structure for Evaluation of Patients With Unclear Diagnosis in Centers for Rare Diseases N/A
Recruiting NCT05499091 - Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN N/A
Completed NCT03954652 - Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH" N/A
Recruiting NCT05703893 - Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
Enrolling by invitation NCT04703179 - Rare and Undiagnosed Disease Research Biorepository
Recruiting NCT04024774 - Diagnostic Research in Patients With Rare Diseases -Solving the Unsolved Rare Diseases
Recruiting NCT06343558 - Gait and Balance Impairment in Rare and Very Rare Neurological Diseases
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Enrolling by invitation NCT04654000 - Rheopheresis as Adjuvant Treatment of Calciphylaxis N/A
Recruiting NCT04651439 - Severe Bullous Drug Eruption and Filgrastim Phase 2/Phase 3